A recent Cancer Genome Atlas Research showed IDH mutations had significant survival prediction in lower grade gliomas (WHO II and III), including oligodendroglioma, oligoastrocytoma and astrocytoma. This evidence concerns the gene IDH2 and central nervous system cancer.